351 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (1900)
- Addiction (16)
- Allergy, Asthma, & Immunology (12)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (28)
- Blood Disorders (38)
- Bone & Muscle (10)
- Cancer
(726)
- Bladder Cancer (14)
- Brain Cancer (25)
- Breast Cancer (70)
- Gastrointestinal (16)
- Gynecologic Cancer (28)
- Head and Neck Cancer (4)
- Kidney Cancer (8)
- Leukemia (75)
- Liver Cancer (10)
- Lung Cancer (62)
- Lymphoma (45)
- (-) Multiple Myeloma (30)
- Pancreatic Cancer (22)
- Prostate Cancer (36)
- Sarcoma (25)
- Skin Cancer (30)
- Solid Tumors (42)
- Thyroid Cancer (1)
- Uveal Melanoma (7)
- Child Development (4)
- COVID-19 (Coronavirus) (37)
- Critical Illness (1)
- Dental (2)
- Developmental Disorders (2)
- Diabetes (22)
- Ear, Nose and Throat (11)
- Endocrine & Metabolic Disease (13)
- Eye (8)
- Gastrointestinal and Digestive Diseases (22)
- Hair and Skin Disorders (2)
- Headaches (5)
- Healthy Volunteers (175)
- Heart Disease (128)
- Infectious Disease (48)
- Insomnia (2)
- (-) Kidney Disease (12)
- Liver Disease (48)
- Lung Disease (32)
- Meniere's Disease (1)
- Neurological Disorders (174)
- Nutrition (4)
- Obesity (9)
- Obstetrics & Gynecology (51)
- Pain Management (1)
- Pediatrics (104)
- Psychiatric Disorders (65)
- Rehabilitation (8)
- Stroke (7)
- Surgery (7)
- Transplant (51)
- Urology (4)
- Vascular Conditions (9)
Displaying 1 - 42 of 42
Study of Daratumumab in Addition to Chemotherapy for Patients with Smoldering Multiple Myeloma (SMM)
Condition: Cancer / Multiple Myeloma
Investigator: Rajshekhar Chakraborty, MD
Status: Currently Recruiting
The purpose of this study is to determine whether patients with high-risk smoldering multiple myeloma when treated with daratumumab in addition to lenalidomide and dexamethasone live longer when compared to patients with high-risk smoldering multiple myeloma patients treated with lenalidomide and dexamethasone. We would also like to know whether the period…
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Currently Recruiting
The purpose of this study is to see if Isatuximab can alter the immune system favorably in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. This study will have two arms. On one arm (control arm), Participants will receive standard transplant procedures and on the other arm (experimental arm),…
Condition: Cancer / Multiple Myeloma
Investigator: Rajshekhar Chakraborty, MD
Status: Currently Recruiting
This study is looking at people who have recently been newly diagnosed with a type of cancer called multiple myeloma (NDMM). The purpose of this study is to learn about the safety, tolerability (how your body reacts to the study drug), and effectiveness (tumor shrinkage) of linvoseltamab (called study drug) in participants with NDMM as a first step in…
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Currently Recruiting
The purpose of this study is to test whether BMS-986393 in combination with other anti-cancer drugs is safe and effective at treating people with multiple myeloma (MM) that has come back after previous treatment (relapsed) or is not responding to current treatment (refractory). The researchers think that the combinations of alnuctamab, mezigdomide, or…
Condition: Cancer / Multiple Myeloma
Investigator: Rajshekhar Chakraborty, MD
Status: Currently Recruiting
This study is the first time REGN5458 will be combined with other cancer therapies. The main goal is to understand if REGN5458 can be given safely with other cancer study treatments, and if so, what dose of REGN5458 should be used for each combination. The investigational drug, REGN5458, is not approved by the Food and Drug Administration (FDA).
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Currently Recruiting
The purpose of this study is to see how teclistamab by itself compares to study treatment combinations that are commonly used to treat multiple myeloma. These study treatment combinations are either pomalidomide, bortezomib and dexamethasone (called PVd) or carfilzomib and dexamethasone (called Kd). The patients will be randomly assigned to on of the study…
Condition: Cancer / Multiple Myeloma
Investigator: Rajshekhar Chakraborty, MD
Status: Currently Recruiting
The purpose of this study is assess the safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in subjects with t(11;14) positive relapsed (comes back) or refractory (did not get better) light chain amyloidosis. Furthermore, the purpose of phase 2 part of this study is to compare the effectiveness of venetoclax and…
Condition: Kidney Disease
Investigator: Gerald Appel, MD
Status: Closed
We are particularly interested in the diseases that cause nephrotic syndrome called Focal and Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), and Membranous Nephropathy (MN). By collecting health information and laboratory samples, our goal is to learn more about diseases and find better ways to prevent and treat people with diseases.…
Condition: Cancer / Multiple Myeloma
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this study is to determine if the investigational therapy called bb2121 is effective in treating multiple myeloma. bb2121 is a type of therapy known as chimeric antigen receptor (CAR) T-cell therapy. T cells are a kind of white blood cell which form part of your body's immune system. Your T cells will be separated from the rest of the…
Condition: Cancer / Multiple Myeloma
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this study is to see if Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by cilta-cel is safe and useful for treating patients with newly diagnosed Multiple Myeloma, as compared with the use of VRd followed by Lenalidomide and Dexamethasone (Rd) therapy. Cilta-cel is a CAR-T cell therapy. In this type of treatment, your white blood…
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Closed
This study will look at the safety of a drug (REGN5458) in patients with multiple myeloma. It will also try to find out what the best dose of REGN5458 is and look for any signs that REGN5458 can help treat your cancer. REGN5458 is investigational, which means it has not been approved by the US Food and Drug Administration (FDA) for any condition.
Condition: Kidney Disease
Investigator: Thomas Nickolas, MD, MS
Status: Closed
The CureGN Bone Study is a prospective study that is assessing the effects of 4-types of kidney disease on the skeleton. In order for us to determine the true effect of kidney disease on bone, we need to determine what healthy bone looks for patients who have the same age, race, sex, and body mass index as the patients with kidney disease. We are looking…
Condition: Cancer / Multiple Myeloma
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this study is to determine if the investigational therapy, bb2121, in combination with other treatments, is safe and effective in treating relapsed and/or refractory multiple myeloma.
Condition: Cancer / Multiple Myeloma
Investigator: Rajshekhar Chakraborty, MD
Status: Closed
You are being asked to participate in this study because you have multiple myeloma that has either returned after your most recent treatment regimen or has not responded to your most recent treatment regimen. Multiple myeloma is a cancer that forms in a type of white blood cell called a plasma cell. Healthy plasma cells help you fight infections by making…
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
You are being asked to take part in this study because you have Multiple Myeloma. This study is being done to learn more about AMG 701 in people with Multiple Myeloma. It will see if AMG 701 is safe and tolerable and whether it causes any side effects. This study will also look at what doses of AMG 701 are safe for people to take and what the effect on…
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
This is a research study. We invite you to participate in this research study because you have been diagnosed with Multiple Myeloma (MM). Your previous treatment(s) has/have not been successful and your cancer is progressing. The purpose of this research study is to see if selinexor (also known as KPT-330) has any effects on your cancer. Selinexor is…
Condition: Cancer / Multiple Myeloma
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this research study is to obtain information on the safety and effectiveness of PBCAR269A to treat certain types of cancers. PBCAR269A is a new investigational treatment for certain types of cancer of the blood, such as multiple myeloma. It is made from a type of blood cells known as T cells. The T cells in PBCAR269A came from people who have…
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of this study is to find out how well Daratumumab works when it is given along with two other drugs called Lenalidomide and Dexamethasone compared to the drug combination of Lenalidomide and Dexamethasone to treat multiple myeloma.
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
We are doing this study to learn if the MMprofiler test can help your doctor in making decisions about your treatment. The MMprofiler genomic test will look at a large number of normal genes. The test will predict risk of your multiple myeloma (MM) by assessing whether these genes are turned on or off in your cancer cells. The purpose of this research is to…
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
This is a research study for subjects who have been diagnosed with multiple myeloma, a cancer of plasmacells (a type of immune cell that produce antibodies) in the bone marrow, that has returned (relapsed) or has not responded (refractory) to your most recent treatment regimen.The subject's disease has also progressed after prior treatment with…
Condition: Kidney Disease
Investigator: Jai Radhakrishnan, MD
Status: Closed
The purpose of this study is to evaluate the safety and effectiveness of an investigational medication in patients with focal segmental glomerulosclerosis (FSGS). The goal is to learn whether the investigational medication may change the amount of protein in the urine and decrease proteinuria.
Condition: Cancer / Multiple Myeloma
Investigator: Yvonne Saenger, MD
Status: Closed
The purpose of this study is to test two imaging techniques, one called whole body diffusion weighted magnetic resonance imaging (WB-DWI MRI), and another called F-18 3-deoxy-3-fluorothymidine PET (F-18-FLT PET). The goal is to see whether these imaging techniques would allow the study doctors to see changes in the size of a tumor earlier for patients with…
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Closed
The main goals of this study are to evaluate the safety of the combination of the study drug radium-223 dichloride plus bortezomib and dexamethasone and to determine the optimal dose of radium-223 dichloride to be used in combination with bortezomib and dexamethasone. Radium-223 dichloride has been approved in some countries for treatment of patients with…
Condition: Kidney Disease
Investigator: Thomas Nickolas, MD, MS
Status: Closed
Kidney disease patients have a variety of severe bone disorders that result in rapid bone loss and fractures. We are doing this research study to determine relationships between bone quality determined from bone imaging and bone biopsy and by non-invasive measures from blood and skin. We are trying to identify non-invasive markers of bone quality in kidney…
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Closed
This study will look to obtain information on the best dose of the research drug, TAK 079, when administered in combination with other approved multiple myeloma treatments for patients with newly diagnosed multiple myeloma. If you participate you will receive either Arm A (TAK-079 in combination with lenalidomide and dexamethasone) or Arm B (TAK-079 in…
Condition: Kidney Disease
Investigator: Jai Radhakrishnan, MD
Status: Closed
This study is for patients with autosomal dominant polycystic kidney disease (ADPKD). The purpose of this study is to test the effectiveness of a study drug called tolvaptan. Tolvaptan continues to be studied in this trial as a possible treatment for ADPKD. ADPKD is a disease that causes kidney cysts (cyst are like fluid-filled balloons), worsening kidney…
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
This is research study for patients who have been newly diagnosed with Multiple Myeloma (MM). Their previous treatments have not been successful and their cancer is progressing. The purpose of this research study is to see if the study drug selinexor (KPT-330) has any effects against their cancer. This study combines the use of two drugs, selinexor (KPT-…
Condition: Kidney Disease
Investigator: Ziad Ali, MD
Status: Closed
Contrast-Induced Nephropathy (CIN) can occur when patients with pre-existing kidney problems undergo procedures that use iodinated contrast media, such as cardiac catheterizations. RenalGuard Therapy was developed to enable the patient to clear the contrast out of their kidney before it can do significant damage. This study aims to enroll patients with…
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of this study is to find out whether treatment with daratumumab and lenalidomide will make your Multiple Myeloma better. There are 2 treatment groups in this study. You will either receive lenalidomide alone or both lenalidomide and daratumumab along with medications to take before and after the daratumumab injection.
Condition: Kidney Disease
Investigator: Gerald Appel, MD
Status: Closed
The purpose of this research study is to understand the way Alport Syndrome affects patients kidneys over time. Alport syndrome is a genetic condition that causes damage to your kidneys over time. Currently there is not much information on the disease. Information about how the body is affected by the disease will be collected, along with medical and family…
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this research study is to explore the drug combination, lenalidomide, bortezomib, and dexamethasone alone or when combined with autologous stem cell transplantation to see what side effects it may have and how well it works for treatment of newly diagnosed multiple myeloma.
Condition: Kidney Disease
Investigator: Wooin Ahn, MD
Status: Closed
Focal Segmental Glomerulosclerosis (FSGS) is a disease in which your kidneys allow an excess amount of protein in your urine. Too much protein in the urine (also called proteinuria) is a medical condition called nephrotic syndrome. The purpose of this clinical trial is to evaluate the safety and effectiveness of the study drug, Acthar, in adult patients…
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to look at what happens (both good and bad) when daratumumab is given with two other drugs called VELCADE and dexamethasone compared to just giving those two drugs, VELCADE and dexamethasone, alone. VELCADE is also known by the name bortezomib. Giving VELCADE and dexamethasone together is standard treatment for advanced multiple…
Condition: Cancer / Multiple Myeloma
Investigator: Siyang Leng, MD
Status: Closed
The purpose of this study is to test the safety, tolerability and anti-tumor activity of the research study drug, pembrolizumab (MK-3475) with or without pomalidomide and low dose dexamethasone in subjects with refractory or relapsed and refractory Multiple Myeloma (rrMM) measured by the rates of response to treatment, disease progression (disease getting…
Condition: Kidney Disease
Investigator: Marcus Pereira, MD, MPH
Status: Closed
This research is being done to learn whether organ transplantation from HIV-positive deceased donors is as safe and effective in HIV-positive recipients as transplants from HIV-negative deceased donors. People with end-stage organ disease and HIV infection, and who qualify for organ transplantation, may join this study.
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
This is a study of a study drug, Carfilzomib in combination with bendamustine and dexamethasone for subjects with newly diagnosed multiple myeloma. The purpose of this study is to find the highest tolerable dose of carfilzomib with the combination of bendamustine and dexamethasone. The response rate and the safety of this drug combination will also be…
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of this study is to compare the effectiveness of venetoclax and dexamethasone versus pomalidomide and dexamethasone in subjects with t(11;14) positive relapsed (comes back) or refractory (did not get better) multiple myeloma.
Condition: Kidney Disease
Investigator: Gerald Appel, MD
Status: Closed
A sign of your kidney disease is the presence of too much protein in your urine. The purpose of this study is to evaluate if the investigational study drug abatacept can decrease the amount of protein in your urine and improve your kidney disease beyond the treatment you have received or are already receiving. Abatacept is being used in an investigational…
Condition: Kidney Disease
Investigator: Marcus Pereira, MD, MPH
Status: Closed
The MK-8228-002 Study is studying the safety and effectiveness of an investigational medication for preventing cytomegalovirus (CMV) disease in adults with kidney transplants. The MK-8228-002 Study is evaluating an investigational medication (known as MK-8228) versus valganciclovir (VGCV). VGCV is an antiviral medication and is the current standard of care…
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
This research study is being done to compare the combination of lenalidomide and dexamethasone followed by autologous peripheral blood stem cell transplant (PBSCT) and lenalidomide and dexamethasone without PBSCT in subjects with untreated multiple myeloma. This comparison will include how many subjects respond to each study treatment combination, how long…
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Closed
Belantamab Mafodotin is a new therapy for patients with Multiple Myeloma. The drug works by combining chemotherapy and immunotherapy approach to treat Multiple Myeloma. The drug is a combination of an antibody against a target on plasma cells called BCMA and a chemotherapeutic agent called MMAF. The drug has shown activity in patients with late relapses of…
Condition: Kidney Disease
Investigator: Pietro Canetta, MD
Status: Closed
The purpose of this study is to assess the most adequate dose of Acthar Gel (ACTH) in patients withIgA nephropathy. Acthar Gel (ACTH) has been approved by the Food and Drug Administration(FDA) for routine clinical use in the treatment of patients with proteinuria and patients withidiopathic nephrotic syndrome such as IgAN.
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE